ABIONYX Pharma Announces Its 2022 Full-year Financial Results

2022 revenues: €5.3 million Reduction of the annual operating loss Cash position of €4 million as of December 31, 2022 Continued clinical development following the succession

Related Keywords

Paris ,France General ,France ,Nicolas Fossiez ,Valutazioni Biologichee Farmacologiche ,Louis Victor Delouvrier ,Iris Pharma ,Arthur Rouill ,University Of Bari ,European Medicines Agency ,Drug Administration ,Valutazioni Biologiche ,Clinical Trials ,Internal Medicine ,Compassionate Access Authorization ,Orphan Drug Designation ,Victor Delouvrier ,Diese Gold Aktie ,Sichern Sie ,Abionyx ,Dharma ,Nnounces ,022 ,Bull ,Ear ,Financial ,Results ,